Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
This phase III trial compares the use of contrast-enhanced multiparametric ultrasound (mp-US) to multiparametric magnetic resonance imaging (mp-MRI) for the diagnosis of clinically significant prostate cancer (PCa). A mp-US is a procedure in which a probe that sends out high-energy sound waves is inserted into the rectum. The sound waves are bounced off internal tissues or organs and make echoes. The echoes form a picture of body tissue called a sonogram. Perflutren lipid michrosphere (Definity) is a contrast agent that uses microbubbles to enhance ultrasound images of the prostate. Doctors hope to learn if the Definity-enhanced mp-US imaging technique can accurately direct targeted biopsy for the detection of clinically significant prostate cancer when compared to standard of care mp-MRI.
Phase:
PHASE3
Details
Lead Sponsor:
Thomas Jefferson University
Collaborators:
Amsterdam UMC, location VUmc Eigen Eindhoven University of Technology GE Healthcare